Intervention
Pharmacological Study
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 103 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownPembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaNCT03126630 · 2018-10-04
ACTIVE_NOT_RECRUITINGPI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryNCT03218826 · 2018-09-24
COMPLETEDPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250 · 2018-08-13
COMPLETEDErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)NCT03210714 · 2018-06-05
ACTIVE_NOT_RECRUITINGCPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung CancerNCT03370159 · 2018-06-01
WITHDRAWNGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNCT03326258 · 2018-04-20
WITHDRAWNEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)NCT03213652 · 2018-04-17
ACTIVE_NOT_RECRUITINGIbrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasNCT03220022 · 2018-03-16
ACTIVE_NOT_RECRUITINGMirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerNCT02996825 · 2017-10-02
COMPLETEDAtezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerNCT03202316 · 2017-08-11
ACTIVE_NOT_RECRUITINGCopanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerNCT03128619 · 2017-08-02
TERMINATEDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGTesting the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerNCT02503722 · 2017-03-23
ACTIVE_NOT_RECRUITINGAtezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsNCT03074513 · 2017-03-03
ACTIVE_NOT_RECRUITINGLung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03
COMPLETEDThe PROMISE Study: Duavee in Women With DCISNCT02694809 · 2017-01-01
COMPLETEDAlternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerNCT02598557 · 2016-12-06
COMPLETEDNeratinib in Treating Older Patients With Stage IV HER2-Positive Breast CancerNCT02673398 · 2016-12-02
COMPLETEDSapanisertib in Treating Patients With Stage IV or Recurrent Lung CancerNCT02417701 · 2016-10-06
COMPLETEDCopper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast CancerNCT02708511 · 2016-08-01
TERMINATEDSelumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT02503358 · 2016-07-21
COMPLETEDCeritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerNCT02321501 · 2016-06-22
ACTIVE_NOT_RECRUITINGDocetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate CancerNCT02516670 · 2016-06-20
TERMINATEDTalazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT02567396 · 2016-06-01
WITHDRAWNErlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerNCT02535338 · 2016-04-11
COMPLETEDCarvedilol in Preventing Heart Failure in Childhood Cancer SurvivorsNCT02717507 · 2016-04-04
COMPLETEDTalazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerNCT02627430 · 2016-03-01
WITHDRAWNEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerNCT02453620 · 2016-02-12
ACTIVE_NOT_RECRUITINGTLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635 · 2016-02-05
TERMINATEDDinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaNCT02484443 · 2016-02-04
COMPLETEDOnalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerNCT02474173 · 2016-01-15
TERMINATEDMEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerNCT02536794 · 2016-01-14
COMPLETEDNiclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerNCT02532114 · 2015-12-31
COMPLETEDEnzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma ExpressionNCT02555189 · 2015-12-01
TERMINATEDRecombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsNCT02495896 · 2015-09-03
ACTIVE_NOT_RECRUITINGBuparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsNCT01971489 · 2015-09-01
WITHDRAWNSelinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerNCT02536495 · 2015-09-01
WITHDRAWNRibociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginNCT02420691 · 2015-08-25
COMPLETEDEnzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate CancerNCT02522715 · 2015-08-13
ACTIVE_NOT_RECRUITINGTaselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerNCT02457910 · 2015-06-01
TERMINATEDTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerNCT02311933 · 2015-05-28
ACTIVE_NOT_RECRUITINGSelinexor in Treating Patients With Relapsed Small Cell Lung CancerNCT02351505 · 2015-05-01
TERMINATEDAzacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT02009436 · 2015-02-09
COMPLETEDTalazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA GenesNCT02286687 · 2014-12-22
ACTIVE_NOT_RECRUITINGmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375 · 2014-11-11
ACTIVE_NOT_RECRUITINGIbrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNCT02109224 · 2014-09-01
TERMINATEDLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08
COMPLETEDErlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionNCT02134886 · 2014-07-01
TERMINATEDTrastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by SurgeryNCT01816035 · 2014-06-01
COMPLETEDSirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung CancerNCT01737502 · 2014-05-14
COMPLETEDPomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active SurveillanceNCT02095145 · 2014-05-08
COMPLETEDPhotodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by SurgeryNCT01854684 · 2014-02-21
COMPLETEDItraconazole in Treating Patients With Biochemically Relapsed Prostate CancerNCT01787331 · 2013-10-29
COMPLETEDTrametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01912625 · 2013-10-28
TERMINATEDPegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung CancerNCT01876446 · 2013-08-29
COMPLETEDCabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency VirusNCT01822522 · 2013-06-21
COMPLETEDAzacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryNCT01886573 · 2013-06-01
TERMINATEDBroccoli Sprout Extract in Treating Patients With Breast CancerNCT01753908 · 2013-05-21
COMPLETEDBrentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaNCT01771107 · 2013-03-08
COMPLETEDRecombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerNCT01727076 · 2013-02-15
COMPLETEDCommon conditions
Recurrent Breast Carcinoma24Triple-Negative Breast Carcinoma17Estrogen Receptor Negative16HER2/Neu Negative15Progesterone Receptor Negative13Stage IIIB Breast Cancer12Stage IV Breast Cancer12Recurrent Non-Small Cell Lung Carcinoma11Recurrent Prostate Carcinoma11Stage IIIC Breast Cancer11Stage IV Breast Cancer AJCC v6 and v711Adult Solid Neoplasm10Stage IV Non-Small Cell Lung Cancer10Estrogen Receptor Positive9Advanced Malignant Solid Neoplasm8Male Breast Carcinoma8Stage IIIA Non-Small Cell Lung Cancer8Stage IIIB Non-Small Cell Lung Cancer8Metastatic Malignant Solid Neoplasm7Metastatic Prostate Carcinoma7Recurrent Ovarian Carcinoma7Stage IIA Breast Cancer7Stage IIB Breast Cancer7Stage IIIA Breast Cancer7Recurrent Renal Cell Carcinoma6
Leading sponsors
National Cancer Institute (NCI)62M.D. Anderson Cancer Center7Roswell Park Cancer Institute7Mayo Clinic3University of Washington3Children's Oncology Group2City of Hope Medical Center2Erin Bertino2Northwestern University2OHSU Knight Cancer Institute2SWOG Cancer Research Network2Albert Einstein College of Medicine1Jonsson Comprehensive Cancer Center1Sanjiv Sam Gambhir1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
Trial status mix
COMPLETED57
TERMINATED22
ACTIVE_NOT_RECRUITING17
WITHDRAWN7
Phase mix
PHASE165
PHASE249
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.